Tumour-associated macrophage polarisation and re-education with immunotherapy

Frontiers in Bioscience - Elite

Volumn 7E, Issue 2, 2015, Pages 334-351

  Josephs, Debra H ^a   Bax, Heather J ^a   Karagiannis, Sophia N ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

ADCC; ADCP; IgE; IgG; M1 macrophages; M2 macrophages; Macrophages; Monoclonal antibodies; Monocytes; Th1 Th2 responses; Tumour immunotherapy; Tumour microenvironment

Indexed keywords

IMMUNOGLOBULIN E ANTIBODY; MONOCLONAL ANTIBODY; IMMUNOGLOBULIN E;

ARTICLE; CANCER IMMUNOTHERAPY; CELL ACTIVITY; CELL POLARITY; CELL SURVIVAL; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY INFILTRATE; MACROPHAGE; METASTASIS; NEOPLASMS; PHENOTYPE; PHYSIOLOGY; POLARIZATION; REPOLARIZATION; SOLID TUMOR; TARGET CELL; THERAPY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANTINEOPLASTIC ACTIVITY; CANCER MODEL; CANCER PATIENT; INFLAMMATION; MACROPHAGE ACTIVATION; NONHUMAN; OUTCOME ASSESSMENT; REVIEW; TH2 CELL;

CELL POLARITY; HUMANS; IMMUNOLOGY; IMMUNOTHERAPY; MACROPHAGES; NEOPLASMS; PHENOTYPE; PHYSIOLOGY; THERAPY; TUMOR MICROENVIRONMENT;

EID: 84919346877     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: 10.2741/E735     Document Type: Article

References (104)

1. A. P. Cardoso, M. L. Pinto, A. T. Pinto, M. I. Oliveira, M. T. Pinto, R. Goncalves, J. B. Relvas, C. Figueiredo, R. Seruca, A. Mantovani, M. Mareel, M. A. Barbosa and M. J. Oliveira: Macrophages stimulate gastric and colorectal cancer invasion through EGFR Y(1086), c-Src, Erk1/2 and Akt phosphorylation and smallGTPase activity. Oncogene, 33(16), 2123-33 (2014) DOI: 10.1038/onc.2013.154
2. L. M. Coussens, L. Zitvogel and A. K. Palucka: Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science, 339(6117), 286-91 (2013) DOI: 10.1126/science.1232227
3. T. Hagemann, F. Balkwill and T. Lawrence: Inflammation and cancer: a double-edged sword. Cancer Cell, 12(4), 300-1 (2007) DOI: 10.1016/j.ccr.2007.10.005
4. A. Mantovani and A. Sica: Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol, 22(2), 231-7 (2010) DOI: 10.1016/j.coi.2010.01.009
5. D. F. Quail and J. A. Joyce: Microenvironmental regulation of tumor progression and metastasis. Nat Med, 19(11), 1423-37 (2013) DOI: 10.1038/nm.3394
6. A. Mantovani: Cancer: Inflaming metastasis. Nature, 457(7225), 36-7 (2009) DOI: 10.1038/457036b
7. C. de Martel, J. Ferlay, S. Franceschi, J. Vignat, F. Bray, D. Forman and M. Plummer: Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol, 13(6), 607-15 (2012) DOI: 10.1016/S1470-2045(12)70137-7
8. B. Z. Qian and J. W. Pollard: Macrophage diversity enhances tumor progression and metastasis. Cell, 141(1), 39-51 (2010) DOI: 10.1016/j.cell.2010.03.014
9. L. Bingle, N. J. Brown and C. E. Lewis: The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol, 196(3), 254-65 (2002) DOI: 10.1002/path.1027
10. R. Virchow: Cellular pathology as based upon physiological and pathological histology. J.B. Lippincott and Co, Philadelphia (1863) No DOI Found
11. F. Bellora, R. Castriconi, A. Dondero, A. Pessino, A. Nencioni, G. Liggieri, L. Moretta, A. Mantovani, A. Moretta and C. Bottino: TLR activation of tumor-associated macrophages from ovarian cancer patients triggers cytolytic activity of NK cells. Eur J Immunol, 44(6), 1814-22 (2014) DOI: 10.1002/eji.201344130
12. E. M. Dijkgraaf, M. Heusinkveld, B. Tummers, L. T. Vogelpoel, R. Goedemans, V. Jha, J. W. Nortier, M. J. Welters, J. R. Kroep and S. H. van der Burg: Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res, 73(8), 2480-92 (2013) DOI: 10.1158/0008-5472.CAN-12-3542
13. A. Mantovani and M. Locati: Tumor-associated macrophages as a paradigm of macrophage plasticity, diversity, and polarization: lessons and open questions. Arterioscler Thromb Vasc Biol, 33(7), 1478-83 (2013) DOI: 10.1161/ATVBAHA.113.300168
14. T. Wang, Y. Ge, M. Xiao, A. Lopez-Coral, R. Azuma, R. Somasundaram, G. Zhang, Z. Wei, X. Xu, F. J. Rauscher, 3rd, M. Herlyn and R. E. Kaufman: Melanoma-derived conditioned media efficiently induce the differentiation of monocytes to macrophages that display a highly invasive gene signature. Pigment Cell Melanoma Res, 25(4), 493-505 (2012) DOI: 10.1111/j.1755-148X.2012.01005.x
15. H. Fujimoto, T. Sangai, G. Ishii, A. Ikehara, T. Nagashima, M. Miyazaki and A. Ochiai: Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression. Int J Cancer, 125(6), 1276-84 (2009) DOI: 10.1002/ijc.24378
16. S. Gazzaniga, A. I. Bravo, A. Guglielmotti, N. van Rooijen, F. Maschi, A. Vecchi, A. Mantovani, J. Mordoh and R. Wainstok: Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J Invest Dermatol, 127(8), 2031-41 (2007) DOI: 10.1038/sj.jid.5700827
17. M. R. Galdiero, C. Garlanda, S. Jaillon, G. Marone and A. Mantovani: Tumor associated macrophages and neutrophils in tumor progression. J Cell Physiol, 228(7), 1404-12 (2013) DOI: 10.1002/jcp.24260
18. C. Garris and M. J. Pittet: Therapeutically reeducating macrophages to treat GBM. Nat Med, 19(10), 1207-8 (2013) DOI: 10.1038/nm.3355
19. S. K. Biswas and A. Mantovani: Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol, 11(10), 889-96 (2010) DOI: 10.1038/ni.1937
20. M. R. Galdiero, E. Bonavita, I. Barajon, C. Garlanda, A. Mantovani and S. Jaillon: Tumor associated macrophages and neutrophils in cancer. Immunobiology, 218(11), 1402-10 (2013) DOI: 10.1016/j.imbio.2013.06.003
21. P. J. Murray, J. E. Allen, S. K. Biswas, E. A. Fisher, D. W. Gilroy, S. Goerdt, S. Gordon, J. A. Hamilton, L. B. Ivashkiv, T. Lawrence, M. Locati, A. Mantovani, F. O. Martinez, J. L. Mege, D. M. Mosser, G. Natoli, J. P. Saeij, J. L. Schultze, K. A. Shirey, A. Sica, J. Suttles, I. Udalova, J. A. van Ginderachter, S. N. Vogel and T. A. Wynn: Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines. Immunity, 41(1), 14-20 (2014) DOI: 10.1016/j.immuni.2014.06.008
22. J. A. Joyce and J. W. Pollard: Microenvironmental regulation of metastasis. Nat Rev Cancer, 9(4), 239-52 (2009) DOI: 10.1038/nrc2618
23. K. W. Kross, J. H. Heimdal, C. Olsnes, J. Olofson and H. J. Aarstad: Tumour-associated macrophages secrete IL-6 and MCP-1 in head and neck squamous cell carcinoma tissue. Acta Otolaryngol, 127(5), 532-9 (2007) DOI: 10.1080/00016480600951384
24. M. Nesbit, H. Schaider, T. H. Miller and M. Herlyn: Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol, 166(11), 6483-90 (2001) DOI: 10.4049/jimmunol.166.11.6483
25. J. L. Orgaz, P. Pandya, R. Dalmeida, P. Karagiannis, B. Sanchez-Laorden, A. Viros, J. Albrengues, F. O. Nestle, A. J. Ridley, C. Gaggioli, R. Marais, S. N. Karagiannis and V. Sanz-Moreno: Diverse matrix metalloproteinase functions regulate cancer amoeboid migration. Nat Commun, 5, 4255 (2014) DOI: 10.1038/ncomms5255
26. C. Devaud, L. B. John, J. A. Westwood, P. K. Darcy and M. H. Kershaw: Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology, 2(8), e25961 (2013) DOI: 10.4161/onci.25961
27. R. Andreesen, B. Hennemann and S. W. Krause: Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives. J Leukoc Biol, 64(4), 419-26 (1998) No DOI Found
28. M. J. Craig and R. D. Loberg: CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases. Cancer Metastasis Rev, 25(4), 611-9 (2006) DOI: 10.1007/s10555-006-9027-x
29. D. E. Sanford, B. A. Belt, R. Z. Panni, A. Mayer, A. D. Deshpande, D. Carpenter, J. B. Mitchem, S. M. Plambeck-Suess, L. A. Worley, B. D. Goetz, A. Wang-Gillam, T. J. Eberlein, D. G. Denardo, S. P. Goedegebuure and D. C. Linehan: Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin Cancer Res, 19(13), 3404-15 (2013) DOI: 10.1158/1078-0432.CCR-13-0525
30. J. Zhang, L. Patel and K. J. Pienta: CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev, 21(1), 41-8 (2010) DOI: 10.1016/j.cytogfr.2009.11.009
31. S. Rozel, C. J. Galban, K. Nicolay, K. C. Lee, S. Sud, C. Neeley, L. A. Snyder, T. L. Chenevert, A. Rehemtulla, B. D. Ross and K. J. Pienta: Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model. J Cell Biochem, 107(1), 58-64 (2009) DOI: 10.1002/jcb.22056
32. B. Z. Qian, J. Li, H. Zhang, T. Kitamura, J. Zhang, L. R. Campion, E. A. Kaiser, L. A. Snyder and J. W. Pollard: CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature, 475(7355), 222-5 (2011) DOI: 10.1038/nature10138
33. J. B. Mitchem, D. J. Brennan, B. L. Knolhoff, B. A. Belt, Y. Zhu, D. E. Sanford, L. Belaygorod, D. Carpenter, L. Collins, D. Piwnica-Worms, S. Hewitt, G. M. Udupi, W. M. Gallagher, C. Wegner, B. L. West, A. Wang-Gillam, P. Goedegebuure, D. C. Linehan and D. G. DeNardo: Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res, 73(3), 1128-41 (2013) DOI: 10.1158/0008-5472.CAN-12-2731
34. S. M. Pyonteck, L. Akkari, A. J. Schuhmacher, R. L. Bowman, L. Sevenich, D. F. Quail, O. C. Olson, M. L. Quick, J. T. Huse, V. Teijeiro, M. Setty, C. S. Leslie, Y. Oei, A. Pedraza, J. Zhang, C. W. Brennan, J. C. Sutton, E. C. Holland, D. Daniel and J. A. Joyce: CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med, 19(10), 1264-72 (2013) DOI: 10.1038/nm.3337
35. G. Germano, R. Frapolli, C. Belgiovine, A. Anselmo, S. Pesce, M. Liguori, E. Erba, S. Uboldi, M. Zucchetti, F. Pasqualini, M. Nebuloni, N. van Rooijen, R. Mortarini, L. Beltrame, S. Marchini, I. Fuso Nerini, R. Sanfilippo, P. G. Casali, S. Pilotti, C. M. Galmarini, A. Anichini, A. Mantovani, M. D'Incalci and P. Allavena: Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell, 23(2), 249-62 (2013) DOI: 10.1016/j.ccr.2013.01.008
36. S. Aharinejad, P. Paulus, M. Sioud, M. Hofmann, K. Zins, R. Schafer, E. R. Stanley and D. Abraham: Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res, 64(15), 5378-84 (2004) DOI: 10.1158/0008-5472.CAN-04-0961
37. P. Paulus, E. R. Stanley, R. Schafer, D. Abraham and S. Aharinejad: Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. Cancer Res, 66(8), 4349-56 (2006) DOI: 10.1158/0008-5472.CAN-05-3523
38. D. G. DeNardo, D. J. Brennan, E. Rexhepaj, B. Ruffell, S. L. Shiao, S. F. Madden, W. M. Gallagher, N. Wadhwani, S. D. Keil, S. A. Junaid, H. S. Rugo, E. S. Hwang, K. Jirstrom, B. L. West and L. M. Coussens: Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov, 1(1), 54-67 (2011) DOI: 10.1158/2159-8274.CD-10-0028
39. S. M. Zeisberger, B. Odermatt, C. Marty, A. H. Zehnder-Fjallman, K. Ballmer-Hofer and R. A. Schwendener: Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer, 95(3), 272-81 (2006) DOI: 10.1038/sj.bjc.6603240
40. K. Hiraoka, M. Zenmyo, K. Watari, H. Iguchi, A. Fotovati, Y. N. Kimura, F. Hosoi, T. Shoda, K. Nagata, H. Osada, M. Ono and M. Kuwano: Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages. Cancer Sci, 99(8), 1595-602 (2008) DOI: 10.1111/j.1349-7006.2008.00880.x
41. N. R. Miselis, Z. J. Wu, N. Van Rooijen and A. B. Kane: Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Mol Cancer Ther, 7(4), 788-99 (2008) DOI: 10.1158/1535-7163.MCT-07-0579
42. T. L. Rogers and I. Holen: Tumour macrophages as potential targets of bisphosphonates. J Transl Med, 9, 177 (2011) DOI: 10.1186/1479-5876-9-177
43. H. L. Pulaski, G. Spahlinger, I. A. Silva, K. McLean, A. S. Kueck, R. K. Reynolds, G. Coukos, J. R. Conejo-Garcia and R. J. Buckanovich: Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. J Transl Med, 7, 49 (2009) DOI: 10.1186/1479-5876-7-49
44. S. P. Bak, J. J. Walters, M. Takeya, J. R. Conejo-Garcia and B. L. Berwin: Scavenger receptor-A-targeted leukocyte depletion inhibits peritoneal ovarian tumor progression. Cancer Res, 67(10), 4783-9 (2007) DOI: 10.1158/0008-5472.CAN-06-4410
45. T. Nagai, M. Tanaka, Y. Tsuneyoshi, B. Xu, S. A. Michie, K. Hasui, H. Hirano, K. Arita and T. Matsuyama: Targeting tumor-associated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor beta. Cancer Immunol Immunother, 58(10), 1577-86 (2009) DOI: 10.1007/s00262-009-0667-x
46. Y. Luo, H. Zhou, J. Krueger, C. Kaplan, S. H. Lee, C. Dolman, D. Markowitz, W. Wu, C. Liu, R. A. Reisfeld and R. Xiang: Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest, 116(8), 2132-2141 (2006) DOI: 10.1172/JCI27648
47. S. Lewen, H. Zhou, H. D. Hu, T. Cheng, D. Markowitz, R. A. Reisfeld, R. Xiang and Y. Luo: A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis. Cancer Immunol Immunother, 57(4), 507-15 (2008) DOI: 10.1007/s00262-007-0389-x
48. S. K. Biswas and C. E. Lewis: NF-kappaB as a central regulator of macrophage function in tumors. J Leukoc Biol, 88(5), 877-84 (2010) DOI: 10.1189/jlb.0310153
49. A. M. Krieg: Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov, 5(6), 471-84 (2006) DOI: 10.1038/nrd2059
50. H. L. Wilson, A. Dar, S. K. Napper, A. Marianela Lopez, L. A. Babiuk and G. K. Mutwiri: Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides. Int Rev Immunol, 25(3-4), 183-213 (2006) DOI: 10.1080/08830180600785868
51. C. Guiducci, A. P. Vicari, S. Sangaletti, G. Trinchieri and M. P. Colombo: Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res, 65(8), 3437-46 (2005)
52. A. M. Krieg: Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene, 27(2), 161-7 (2008) DOI: 10.1038/sj.onc.1210911
53. A. Carpentier, P. Metellus, R. Ursu, S. Zohar, F. Lafitte, M. Barrie, Y. Meng, M. Richard, C. Parizot, F. Laigle-Donadey, G. Gorochov, D. Psimaras, M. Sanson, A. Tibi, O. Chinot and A. F. Carpentier: Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro Oncol, 12(4), 401-8 (2010) DOI: 10.1093/neuonc/nop047
54. J. S. Weber, H. Zarour, B. Redman, U. Trefzer, S. O'Day, A. J. van den Eertwegh, E. Marshall and S. Wagner: Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. Cancer, 115(17), 3944-54 (2009) DOI: 10.1002/cncr.24473
55. C. S. Zent, B. J. Smith, Z. K. Ballas, J. E. Wooldridge, B. K. Link, T. G. Call, T. D. Shanafelt, D. A. Bowen, N. E. Kay, T. E. Witzig and G. J. Weiner: Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leuk Lymphoma, 53(2), 211-7 (2012) DOI: 10.3109/10428194.2011.608451
56. E. J. Hennessy, A. E. Parker and L. A. O'Neill: Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov, 9(4), 293-307 (2010) DOI: 10.1038/nrd3203
57. I. N. Buhtoiarov, P. M. Sondel, J. M. Wigginton, T. N. Buhtoiarova, E. M. Yanke, D. A. Mahvi and A. L. Rakhmilevich: Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages. Immunology, 132(2), 226-39 (2011) DOI: 10.1111/j.1365-2567.2010.03357.x
58. G. L. Beatty, E. G. Chiorean, M. P. Fishman, B. Saboury, U. R. Teitelbaum, W. Sun, R. D. Huhn, W. Song, D. Li, L. L. Sharp, D. A. Torigian, P. J. O'Dwyer and R. H. Vonderheide: CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science, 331(6024), 1612-6 (2011) DOI: 10.1126/science.1198443
59. A. A. Chaudhuri, A. Y. So, N. Sinha, W. S. Gibson, K. D. Taganov, R. M. O'Connell and D. Baltimore: MicroRNA-125b potentiates macrophage activation. J Immunol, 187(10), 5062-8 (2011) DOI: 10.4049/jimmunol.1102001
60. R. M. O'Connell, K. D. Taganov, M. P. Boldin, G. Cheng and D. Baltimore: MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A, 104(5), 1604-9 (2007) DOI: 10.1073/pnas.0610731104
61. E. Zonari, F. Pucci, M. Saini, R. Mazzieri, L. S. Politi, B. Gentner and L. Naldini: A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective antitumor responses in mice. Blood, 122(2), 243-52 (2013) DOI: 10.1182/blood-2012-08-449306
62. A. M. Scott, J. D. Wolchok and L. J. Old: Antibody therapy of cancer. Nat Rev Cancer, 12(4), 278-87 (2012) DOI: 10.1038/nrc3236
63. L. M. Weiner, J. C. Murray and C. W. Shuptrine: Antibody-based immunotherapy of cancer. Cell, 148(6), 1081-4 (2012) DOI: 10.1016/j.cell.2012.02.034
64. S. Malas, M. Harrasser, K. E. Lacy and S. N. Karagiannis: Antibody therapies for melanoma: New and emerging opportunities to activate immunity (Review). Oncology reports (2014) DOI: 10.3892/or.2014.3275
65. B. Petricevic, J. Laengle, J. Singer, M. Sachet, J. Fazekas, G. Steger, R. Bartsch, E. Jensen-Jarolim and M. Bergmann: Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. J Transl Med, 11, 307 (2013) DOI: 10.1186/1479-5876-11-307
66. E. Hatjiharissi, L. Xu, D. D. Santos, Z. R. Hunter, B. T. Ciccarelli, S. Verselis, M. Modica, Y. Cao, R. J. Manning, X. Leleu, E. A. Dimmock, A. Kortsaris, C. Mitsiades, K. C. Anderson, E. A. Fox and S. P. Treon: Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood, 110(7), 2561-4 (2007) DOI: 10.1182/blood-2007-01-070656
67. U. Bilitewski: Determination of immunomodulatory effects: focus on functional analysis of phagocytes as representatives of the innate immune system. Anal Bioanal Chem, 391(5), 1545-54 (2008) DOI: 10.1007/s00216-008-2089-6
68. R. Braster, T. O'Toole and M. van Egmond: Myeloid cells as effector cells for monoclonal antibody therapy of cancer. Methods, 65(1), 28-37 (2014) DOI: 10.1016/j.ymeth.2013.06.020
69. L. G. Presta: Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol, 20(4), 460-70 (2008) DOI: 10.1016/j.coi.2008.06.012
70. N. Gul, L. Babes, K. Siegmund, R. Korthouwer, M. Bogels, R. Braster, G. Vidarsson, T. L. ten Hagen, P. Kubes and M. van Egmond: Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J Clin Invest, 124(2), 812-23 (2014) DOI: 10.1172/JCI66776
71. K. D. Grugan, F. L. McCabe, M. Kinder, A. R. Greenplate, B. C. Harman, J. E. Ekert, N. van Rooijen, G. M. Anderson, J. A. Nemeth, W. R. Strohl, R. E. Jordan and R. J. Brezski: Tumor-associated macrophages promote invasion while retaining Fc-dependent antitumor function. J Immunol, 189(11), 5457-66 (2012) DOI: 10.4049/jimmunol.1201889
72. P. Karagiannis, A. E. Gilbert, D. H. Josephs, N. Ali, T. Dodev, L. Saul, I. Correa, L. Roberts, E. Beddowes, A. Koers, C. Hobbs, S. Ferreira, J. L. Geh, C. Healy, M. Harries, K. M. Acland, P. J. Blower, T. Mitchell, D. J. Fear, J. F. Spicer, K. E. Lacy, F. O. Nestle and S. N. Karagiannis: IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Invest, 123(4), 1457-74 (2013) DOI: 10.1172/JCI65579
73. T. R. Simpson, F. Li, W. Montalvo-Ortiz, M. A. Sepulveda, K. Bergerhoff, F. Arce, C. Roddie, J. Y. Henry, H. Yagita, J. D. Wolchok, K. S. Peggs, J. V. Ravetch, J. P. Allison and S. A. Quezada: Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med, 210(9), 1695-710 (2013) DOI: 10.1084/jem.20130579
74. V. Minard-Colin, Y. Xiu, J. C. Poe, M. Horikawa, C. M. Magro, Y. Hamaguchi, K. M. Haas and T. F. Tedder: Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood, 112(4), 1205-13 (2008) DOI: 10.1182/blood-2008-01-135160
75. M. Horikawa, V. Minard-Colin, T. Matsushita and T. F. Tedder: Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice. J Clin Invest, 121(11), 4268-80 (2011) DOI: 10.1172/JCI59266
76. E. Oflazoglu, I. J. Stone, K. A. Gordon, I. S. Grewal, N. van Rooijen, C. L. Law and H. P. Gerber: Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30. Blood, 110(13), 4370-2 (2007) DOI: 10.1182/blood-2007-06-097014
77. E. Oflazoglu, I. J. Stone, L. Brown, K. A. Gordon, N. van Rooijen, M. Jonas, C. L. Law, I. S. Grewal and H. P. Gerber: Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40. Br J Cancer, 100(1), 113-7 (2009) DOI: 10.1038/sj.bjc.6604812
78. W. K. Weng and R. Levy: Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol, 21(21), 3940-7 (2003) DOI: 10.1200/JCO.2003.05.013
79. E. Jensen-Jarolim, G. Achatz, M. C. Turner, S. Karagiannis, F. Legrand, M. Capron, M. L. Penichet, J. A. Rodriguez, A. G. Siccardi, L. Vangelista, A. B. Riemer and H. Gould: AllergoOncology: the role of IgE-mediated allergy in cancer. Allergy, 63(10), 1255-66 (2008) DOI: 10.1111/j.1398-9995.2008.01768.x
80. S. N. Karagiannis, D. H. Josephs, P. Karagiannis, A. E. Gilbert, L. Saul, S. M. Rudman, T. Dodev, A. Koers, P. J. Blower, C. Corrigan, A. J. Beavil, J. F. Spicer, F. O. Nestle and H. J. Gould: Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application. Cancer Immunol Immunother, 61(9), 1547-64 (2012) DOI: 10.1007/s00262-011-1162-8
81. M. Dechant and T. Valerius: IgA antibodies for cancer therapy. Critical reviews in oncology/hematology, 39(1-2), 69-77 (2001) DOI: 10.1016/S1040-8428(01)00105-6
82. H. P. Vollmers and S. Brandlein: Natural antibodies and cancer. New biotechnology, 25(5), 294-8 (2009) DOI: 10.1016/j.nbt.2009.03.016
83. S. Brandlein, T. Pohle, N. Ruoff, E. Wozniak, H. K. Muller-Hermelink and H. P. Vollmers: Natural IgM antibodies and immunosurveillance mechanisms against epithelial cancer cells in humans. Cancer Res, 63(22), 7995-8005 (2003) No DOI Found
84. T. Pohle, S. Brandlein, N. Ruoff, H. K. Muller-Hermelink and H. P. Vollmers: Lipoptosis: tumor-specific cell death by antibody-induced intracellular lipid accumulation. Cancer Res, 64(11), 3900-6 (2004) DOI: 10.1158/0008-5472.CAN-03-3149
85. E. Jensen-Jarolim and G. Pawelec: The nascent field of AllergoOncology. Cancer Immunol Immunother, 61(9), 1355-7 (2012) DOI: 10.1007/s00262-012-1315-4
86. D. H. Josephs, J. F. Spicer, P. Karagiannis, H. J. Gould and S. N. Karagiannis: IgE immunotherapy: a novel concept with promise for the treatment of cancer. MAbs, 6(1), 54-72 (2014) DOI: 10.4161/mabs.27029
87. D. H. Josephs, J. F. Spicer, C. J. Corrigan, H. J. Gould and S. N. Karagiannis: Epidemiological associations of allergy, IgE and cancer. Clin Exp Allergy, 43(10), 1110-23 (2013) No DOI Found
88. E. Nagy, I. Berczi and A. H. Sehon: Growth inhibition of murine mammary carcinoma by monoclonal IgE antibodies specific for the mammary tumor virus. Cancer Immunol Immunother, 34(1), 63-9 (1991) DOI: 10.1007/BF01741326
89. T. R. Daniels, R. K. Leuchter, R. Quintero, G. Helguera, J. A. Rodriguez, O. Martinez-Maza, B. C. Schultes, C. F. Nicodemus and M. L. Penichet: Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells. Cancer Immunol Immunother, 61(7), 991-1003 (2012) DOI: 10.1007/s00262-011-1150-z
90. P. Z. Teo, P. J. Utz and J. A. Mollick: Using the allergic immune system to target cancer: activity of IgE antibodies specific for human CD20 and MUC1. Cancer Immunol Immunother, 61(12), 2295-309 (2012) DOI: 10.1007/s00262-012-1299-0
91. M. H. Kershaw, P. K. Darcy, J. A. Trapani and M. J. Smyth: The use of chimeric human Fc(epsilon) receptor I to redirect cytotoxic T lymphocytes to tumors. J Leukoc Biol, 60(6), 721-8 (1996) No DOI Found
92. M. H. Kershaw, P. K. Darcy, J. A. Trapani, D. MacGregor and M. J. Smyth: Tumor-specific IgE-mediated inhibition of human colorectal carcinoma xenograft growth. Oncol Res, 10(3), 133-42 (1998) No DOI Found
93. S. M. Rudman, D. H. Josephs, H. Cambrook, P. Karagiannis, A. E. Gilbert, T. Dodev, J. Hunt, A. Koers, A. Montes, L. Taams, S. Canevari, M. Figini, P. J. Blower, A. J. Beavil, C. F. Nicodemus, C. Corrigan, S. B. Kaye, F. O. Nestle, H. J. Gould, J. F. Spicer and S. N. Karagiannis: Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcvarepsilonRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity. Clin Exp Allergy, 41(10), 1400-13 (2011) DOI: 10.1111/j.1365-2222.2011.03770.x
94. L. Saul, D. H. Josephs, K. Cutler, A. Bradwell, P. Karagiannis, C. Selkirk, H. J. Gould, P. Jones, J. F. Spicer and S. N. Karagiannis: Comparative reactivity of human IgE to cynomolgus monkey and human effector cells and effects on IgE effector cell potency. MAbs, 6(2), 509-22 (2014) DOI: 10.4161/mabs.27828
95. E. A. Nigro, E. Soprana, A. T. Brini, A. Ambrosi, V. A. Yenagi, D. Dombrowicz, A. G. Siccardi and L. Vangelista: An antitumor cellular vaccine based on a mini-membrane IgE. Journal of immunology, 188(1), 103-10 (2012) DOI: 10.4049/jimmunol.1101842
96. A. B. Riemer, E. Untersmayr, R. Knittelfelder, A. Duschl, H. Pehamberger, C. C. Zielinski, O. Scheiner and E. Jensen-Jarolim: Active induction of tumor-specific IgE antibodies by oral mimotope vaccination. Cancer Res, 67(7), 3406-11 (2007) DOI: 10.1158/0008-5472.CAN-06-3758
97. P. Karagiannis, J. Singer, J. Hunt, S. K. Gan, S. M. Rudman, D. Mechtcheriakova, R. Knittelfelder, T. R. Daniels, P. S. Hobson, A. J. Beavil, J. Spicer, F. O. Nestle, M. L. Penichet, H. J. Gould, E. Jensen-Jarolim and S. N. Karagiannis: Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol Immunother, 58(6), 915-30 (2009) DOI: 10.1007/s00262-008-0607-1
98. S. N. Karagiannis, Q. Wang, N. East, F. Burke, S. Riffard, M. G. Bracher, R. G. Thompson, S. R. Durham, L. B. Schwartz, F. R. Balkwill and H. J. Gould: Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur J Immunol, 33(4), 1030-40 (2003) DOI: 10.1002/eji.200323185
99. S. N. Karagiannis, M. G. Bracher, J. Hunt, N. McCloskey, R. L. Beavil, A. J. Beavil, D. J. Fear, R. G. Thompson, N. East, F. Burke, R. J. Moore, D. D. Dombrowicz, F. R. Balkwill and H. J. Gould: IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells. J Immunol, 179(5), 2832-43 (2007)
100. S. N. Karagiannis, M. G. Bracher, R. L. Beavil, A. J. Beavil, J. Hunt, N. McCloskey, R. G. Thompson, N. East, F. Burke, B. J. Sutton, D. Dombrowicz, F. R. Balkwill and H. J. Gould: Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells. Cancer Immunol Immunother, 57(2), 247-63 (2008) DOI: 10.1007/s00262-007-0371-7
101. M. Bracher, H. J. Gould, B. J. Sutton, D. Dombrowicz and S. N. Karagiannis: Three-colour flow cytometric method to measure antibody-dependent tumour cell killing by cytotoxicity and phagocytosis. J Immunol Methods, 323(2), 160-71 (2007) DOI: 10.1016/j.jim.2007.04.009
102. S. N. Karagiannis, F. O. Nestle and H. J. Gould: IgE interacts with potent effector cells against tumours: ADCC and ADCP. In: Cancer and IgE. Humana Press, (2010) DOI: 10.1007/978-1-60761-451-7-8
103. M. Yamaguchi, C. S. Lantz, H. C. Oettgen, I. M. Katona, T. Fleming, I. Miyajima, J. P. Kinet and S. J. Galli: IgE enhances mouse mast cell Fc(epsilon)RI expression in vitro and in vivo: evidence for a novel amplification mechanism in IgE-dependent reactions. J Exp Med, 185(4), 663-72 (1997) DOI: 10.1084/jem.185.4.663
104. H. A. Smith and Y. Kang: The metastasis-promoting roles of tumor-associated immune cells. Journal of molecular medicine, 91(4), 411-29 (2013) DOI: 10.1007/s00109-013-1021-5